Health Condition 1: L918- Other hypertrophic disorders of the skin
Conditions
Interventions
Intervention1: Intralesional injection of combination of 5-Fluorouracil (5-FU) and Triamcinolone acetonide (TAC): Group A will receive intralesional TAC + 5-FU in the ratio of 1:9, prepared by taking
1: Mild itch
2: Moderate itch
3: Severe itch, (4) POSAS score (5) Adverse effects: ulceration, telangiectasia, skin atrophy, pigmentary changes etc.
Control Intervention1: Intralesional injection of Triamcinolone acetonide (TAC) a
Sponsors
Lok Nayak Hospital
Eligibility
Inclusion criteria
Inclusion criteria: -All patients between 18-60 years, having keloid scars with maximum scar size of 20 cm2. -If one patient has multiple scars, no more than two scar sites will be included in the study.
Exclusion criteria
Exclusion criteria: -Pregnancy and lactation -Patients with co-morbidities like uncontrolled diabetes, hypertension, cardio-pulmonary disease, chronic liver / kidney disease with deranged LFT/KFT. -Any patient with history of treatment with intralesional TAC and /or 5-FU injection in previous 6 months for the same site. -Infected keloids
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical scar assessment by Vancouver Scar Scale (VSS) parameters of scar height, pliability, vascularity & pigmentation.Timepoint: Before 1st session (pre-drug), at every session and till last follow up at monthly intervals for subsequent 2 months after the last session. | — |
Secondary
| Measure | Time frame |
|---|---|
| Pain, Pruritis, Telangiectasia, Ulceration, Infection, Atrophy, Pigmentary changes, POSAS score, any other.Timepoint: Before 1st session (pre-drug), at every session and till last follow up at monthly intervals for subsequent 2 months after the last session. | — |
Countries
India
Contacts
Public ContactDr Priyadarshini CA
Lok Nayak Hospital and associated Maulana Azad Medical College
Outcome results
None listed